Oxford Immunotec Global (OXFD) Upgraded to Sell at BidaskClub
BidaskClub upgraded shares of Oxford Immunotec Global (NASDAQ:OXFD) from a strong sell rating to a sell rating in a report published on Saturday morning.
Several other equities research analysts also recently weighed in on OXFD. Zacks Investment Research raised Oxford Immunotec Global from a hold rating to a buy rating and set a $16.00 price target for the company in a report on Friday, August 3rd. ValuEngine downgraded Oxford Immunotec Global from a hold rating to a sell rating in a report on Monday, July 30th. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. Oxford Immunotec Global has a consensus rating of Buy and a consensus price target of $17.80.
Shares of NASDAQ OXFD opened at $15.50 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 5.39 and a quick ratio of 4.86. The stock has a market capitalization of $390.29 million, a price-to-earnings ratio of -11.40 and a beta of -0.20. Oxford Immunotec Global has a fifty-two week low of $10.00 and a fifty-two week high of $17.41.
In related news, CEO Peter Wrighton-Smith sold 40,000 shares of Oxford Immunotec Global stock in a transaction dated Friday, September 7th. The stock was sold at an average price of $14.95, for a total transaction of $598,000.00. Following the completion of the sale, the chief executive officer now owns 525,296 shares of the company’s stock, valued at $7,853,175.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global stock in a transaction dated Wednesday, August 1st. The stock was sold at an average price of $13.15, for a total value of $39,450.00. The disclosure for this sale can be found here. Insiders own 6.61% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in OXFD. Bank of Montreal Can acquired a new position in Oxford Immunotec Global in the second quarter valued at approximately $132,000. State Board of Administration of Florida Retirement System acquired a new position in Oxford Immunotec Global in the second quarter valued at approximately $140,000. Quantitative Systematic Strategies LLC acquired a new position in Oxford Immunotec Global in the first quarter valued at approximately $177,000. JPMorgan Chase & Co. lifted its holdings in Oxford Immunotec Global by 258.0% in the first quarter. JPMorgan Chase & Co. now owns 19,554 shares of the company’s stock valued at $243,000 after acquiring an additional 14,092 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in Oxford Immunotec Global by 84.7% in the second quarter. Renaissance Technologies LLC now owns 21,058 shares of the company’s stock valued at $271,000 after acquiring an additional 9,658 shares during the period. 91.78% of the stock is owned by hedge funds and other institutional investors.
About Oxford Immunotec Global
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.
Read More: What is a Tariff?
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.